MedTrace Logo

A Study of CAT-1004 Biomarkers in Healthy Subjects

NCT01670773 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2012-10-30

No results posted yet for this study

Summary

This study is being conducted to assess mechanistic blood biomarkers of CAT-1004 in healthy humans.

Conditions

  • Assessment of Mechanistic Blood Biomarkers in Healthy Humans

Interventions

DRUG

CAT-1004

DRUG

Salsalate + DHA

DRUG

Placebo

Sponsors & Collaborators

  • Catabasis Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Joanne Donovan, MD, PhD · Catabasis

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01670773 on ClinicalTrials.gov